By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vtesse 

910 Clopper Road
Suite 220S
Gaithersburg  Maryland  20878  U.S.A.
Phone: 1-240-801-9261 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Sucampo (SCMP) Pays $200 Million Upfront for Rare Disease Biotech Vtesse 4/3/2017 5:56:52 AM
Vtesse Completes Enrollment Of Phase IIb/III Pivotal Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 3/15/2017 6:20:19 AM
Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 1/11/2017 6:04:22 AM
Vtesse Announces Appointment Of Jason Meyenburg As Chief Commercial Officer 1/4/2017 7:51:43 AM
Vtesse Receives Rare Pediatric Disease Designation By The FDA For VTS-270 For The Treatment Of Niemann-Pick Type C1 Disease 11/29/2016 6:35:12 AM
Medicines And Healthcare Products Regulatory Agency ("MHRA") Designates VTS-270 As A Promising Innovative Medicine 11/2/2016 7:33:08 AM
Vtesse Announces Dosing Of First Patient In Germany For Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 10/5/2016 6:40:19 AM
Vtesse Bags Another $17 Million to Support Further Product Development and Expand Ongoing Clinical Trials 7/25/2016 6:21:53 AM
Vtesse Advances Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease With Dose Selection For Evaluation In Second And Final Portion Of Trial And Expansion Into Europe 5/23/2016 6:18:33 AM
Vtesse Announces Phase 1/2 Clinical Data Showing Slowing Of Disease Progression From VTS-270 Treatment For Niemann-Pick Type C1 Disease 3/4/2016 6:13:55 AM
//-->